Misonix Reports Fourth Quarter and Fiscal Year 2009 Financi...(246947 199237 Stockholders' eq...),Health

Date:10/1/2009

246,947 199,237 Stockholders' equity: Capital stock, $0.01 par value - shares authorized 20,000,000; 7,079,169 issued, and 7,001,369 outstanding, respectively 70,792 70,792 Additional paid-in capital 25,251,412 25,052,539 Accumulated deficit (3,824,003) (6,630,170) Accumulated other comprehensive income (348,936) 361,707 Treasury stock, 77,800 shares (412,424) (412,424) -------- -------- Total stockholders' equity 20,736,841 18,442,444 ---------- ---------- Total liabilities and stockholders' equity $35,163,406 $37,250,074 =========== =========== MISONIX, INC. And Subsidiaries Consolidated Statements of Operations Derived from audited Unaudited financial statements Three Months Ended Twelve Months Ended June 30, June 30, 2009 2008 2009 2008 ---- ---- ---- ---- Net sales $10,464,809 $10,555,488 $39,790,155 $41,144,139 Cost of goods sold 6,312,135 6,368,618 23,786,201 23,378,587 --------- --------- ---------- ---------- Gross profit 4,152,674 4,186,870 16,003,954 17,765,552 Selling expenses 2,335,044 2,041,159 6,764,338 7,314,684 General and administrative expenses 2,061,944 2,922,326 9,009,280 10,518,550 Research and development expe
'/>"/>

SOURCE Misonix, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10
Related medicine technology :

1. Misonix Schedules Fourth Quarter and Fiscal Year 2009 Financial Results Conference Call; October 1, 2009 at 4:30 p.m. Eastern
2. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
3. Spherix Reports Second Quarter Earnings
4. Tapestry Reports Second Quarter 2007 Results
5. Callisto Reports on Second-Quarter 2007 Milestones
6. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
7. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
8. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
9. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
10. Biopure Reports on Meeting with the FDA
11. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors